Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3491
| Subject | Predicate | Object | Context |
|---|---|---|---|
| dailymed-drugs:3491 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:3491 | rdf:type | dailymed-instance:drugs | lld:dailymed |
| dailymed-drugs:3491 | rdfs:label | Levocarnitine (Injection, Solution) | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:dosage | Levocarnitine Injection, USP is administered intravenously. Metabolic Disorders: The recommended dose is 50 mg/kg given as a slow 2-3 minute bolus injection or by infusion. Often a loading dose is given in patients with severe metabolic crisis, followed by an equivalent dose over the following 24 hours. It should be administered q3h or q4h, and never less than q6h either by infusion or by intravenous injection. All subsequent daily doses are recommended to be in the range of 50 mg/kg or as therapy may require. The highest dose administered has been 300 mg/kg. It is recommended that a plasma carnitine concentration be obtained prior to beginning this parenteral therapy. Weekly and monthly monitoring is recommended as well. This monitoring should include blood chemistries, vital signs, plasma carnitine concentrations (the plasma free carnitine concentration should be between 35 and 60��mol/L) and overall clinical condition. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:clinicalP... | Levocarnitine is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. In skeletal and cardiac muscle, fatty acids are the main substrate for energy production. Primary systemic carnitine deficiency is characterized by low concentrations of levocarnitine in plasma, RBC, and/or tissues. It has not been possible to determine which symptoms are due to carnitine deficiency and which are due to an underlying organic acidemia, as symptoms of both abnormalities may be expected to improve with levocarnitine. The literature reports that carnitine can promote the excretion of excess organic or fatty acids in patients with defects in fatty acid metabolism and/or specific organic acidopathies that bioaccumulate acylCoA esters. Secondary carnitine deficiency can be a consequence of inborn errors of metabolism. Levocarnitine may alleviate the metabolic abnormalities of patients with inborn errors that result in accumulation of toxic organic acids. Conditions for which this effect has been demonstrated are: glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency.Autointoxication occurs in these patients due to the accumulations of acylCoA compounds that disrupt intermediary metabolism. The subsequent hydrolysis of the acylCoA compound to its free acid results in acidosis which can be life threatening. Levocarnitine clears the acylCoA compound by formation of acylcarnitine, which is quickly excreted. Carnitine deficiency is defined biochemically as abnormally lowplasma concentrations of free carnitine, less than 20��mol/L at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. In premature infants and newborns, secondary deficiency is defined as plasma levocarnitine concentrations below age related normal concentrations. | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:activeIng... | dailymed-ingredient:levocar... | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:contraind... | None known. | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:activeMoi... | dailymed-ingredient:levocar... | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:inactiveI... | dailymed-ingredient:water | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:precautio... | Carcinogenesis, mutagenesis, impairment of fertility: Mutagenicity tests performed in Salmonella typhimurium, Saccharomyces cerevisiae, and Schizosaccharomyces pombe indicate that levocarnitine is not mutagenic. No long-term animal studies have been performed to evaluate the carcinogenic potential of levocarnitine.<br/>Pregnancy:<br/>Pregnancy Category B.: Reproductive studies have been performed in rats and rabbits at doses up to 3.8 times the human dose on the basis of surface area and have revealed no evidence of impaired fertility or harm to the fetus due to Levocarnitine. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.<br/>Nursing mothers: Levocarnitine supplementation in nursing mothers has not been specifically studied. Studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine. In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against the benefits of levocarnitine supplementation to the mother. Consideration may be given to discontinuation of nursing or of levocarnitine treatment.<br/>Pediatric use: See DOSAGE AND ADMINISTRATION. | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:overdosag... | There have been no reports of toxicity from levocarnitine overdosage. Levocarnitine is easily removed from plasma by dialysis. The intravenous LDof levocarnitine in rats is 5.4 g/kg and oral LDof levocarnitine in mice is 19.2 g/kg. Large doses of levocarnitine may cause diarrhea. | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:genericMe... | Levocarnitine | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:fullName | Levocarnitine (Injection, Solution) | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:adverseRe... | Transient nausea and vomiting have been observed. Less frequent adverse reactions are body odor, nausea, and gastritis. An incidence for these reactions is difficult to estimate due to the confounding effects of the underlying pathology. Seizures have been reported to occur in patients, with or without pre-existing seizure activity, receiving either oral or intravenous levocarnitine. In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported. | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:warning | None. | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:indicatio... | For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:represent... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:3491 | dailymed-instance:name | Levocarnitine | lld:dailymed |
| http://www4.wiwiss.fu-berli... | dailymed-instance:producesD... | dailymed-drugs:3491 | lld:dailymed |